Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer

Simple item page
aut.relation.issue5
aut.relation.journalBiology (Basel)
aut.relation.startpage697
aut.relation.volume12
dc.contributor.authorLi, Jiawei
dc.contributor.authorGoh, Eyleen LK
dc.contributor.authorHe, Ji
dc.contributor.authorLi, Yan
dc.contributor.authorFan, Zhimin
dc.contributor.authorYu, Zhigang
dc.contributor.authorYuan, Peng
dc.contributor.authorLiu, Dong-Xu
dc.date.accessioned2023-05-30T01:59:34Z
dc.date.available2023-05-30T01:59:34Z
dc.date.issued2023-05-09
dc.description.abstractBreast cancer is now the most common cancer worldwide, and it is also the main cause of cancer-related death in women. Survival rates for female breast cancer have significantly improved due to early diagnosis and better treatment. Nevertheless, for patients with advanced or metastatic breast cancer, the survival rate is still low, reflecting a need for the development of new therapies. Mechanistic insights into metastatic breast cancer have provided excellent opportunities for developing novel therapeutic strategies. Although high-throughput approaches have identified several therapeutic targets in metastatic disease, some subtypes such as triple-negative breast cancer do not yet have an apparent tumor-specific receptor or pathway to target. Therefore, exploring new druggable targets in metastatic disease is a high clinical priority. In this review, we summarize the emerging intrinsic therapeutic targets for metastatic breast cancer, including cyclin D-dependent kinases CDK4 and CDK6, the PI3K/AKT/mTOR pathway, the insulin/IGF1R pathway, the EGFR/HER family, the JAK/STAT pathway, poly(ADP-ribose) polymerases (PARP), TROP-2, Src kinases, histone modification enzymes, activated growth factor receptors, androgen receptors, breast cancer stem cells, matrix metalloproteinases, and immune checkpoint proteins. We also review the latest development in breast cancer immunotherapy. Drugs that target these molecules/pathways are either already FDA-approved or currently being tested in clinical trials.
dc.identifier.citationBiology (Basel), ISSN: 2079-7737 (Print); 2079-7737 (Online), MDPI AG, 12(5), 697-. doi: 10.3390/biology12050697
dc.identifier.doi10.3390/biology12050697
dc.identifier.issn2079-7737
dc.identifier.issn2079-7737
dc.identifier.urihttps://hdl.handle.net/10292/16185
dc.languageeng
dc.publisherMDPI AG
dc.relation.urihttps://www.mdpi.com/2079-7737/12/5/697
dc.rights.accessrightsOpenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectPARP
dc.subjectTNBC
dc.subjectTROP-2
dc.subjectbreast cancer
dc.subjectchemoimmunotherapy
dc.subjecthistone deacetylase inhibitor
dc.subjectimmunotherapy
dc.subjectmetastatic breast cancer
dc.subjecttargeted therapy
dc.subjecttherapeutic target
dc.subject31 Biological Sciences
dc.subjectClinical Trials and Supportive Activities
dc.subjectBreast Cancer
dc.subjectClinical Research
dc.subjectCancer
dc.subjectStem Cell Research
dc.subject5.1 Pharmaceuticals
dc.subject4 Detection, screening and diagnosis
dc.subject4.1 Discovery and preclinical testing of markers and technologies
dc.subject5 Development of treatments and therapeutic interventions
dc.subjectCancer
dc.subject3 Good Health and Well Being
dc.subject06 Biological Sciences
dc.subject31 Biological sciences
dc.titleEmerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
dc.typeJournal Article
pubs.elements-id507671
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Li et al._2023_Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer..pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
Collections
School of Science - Te Kura Pūtaiao